AutoGenomics IPO Will Support Trial Of HPV Test On Infiniti Analyzer
This article was originally published in The Gray Sheet
AutoGenomics is seeking to fund a clinical study of its HPV-QUAD human papillomavirus screening test through an initial public stock offering worth up to $86.3 million (see chart: "1AutoGenomics IPO")
You may also be interested in...
Molecular diagnostics firm AutoGenomics seeks to raise up to $65 million in an initial public offering. IlluminOss raises $28 mil. for fracture repair device. LoneStar Heart gets $20 million for heart failure implant. More financings.
Hologic's purchase of molecular diagnostics firm Third Wave Technologies for $580 million provides a platform for near-term entry into the expanding, $200 million U.S. market for human papillomavirus testing
When Mads Øvlisen was persuaded by his father-in-law to join the family business, Novo Industri, in 1974 for a short stint in the legal department, little did he know it would the beginning of a lifetime of service to the company that he helped to shape into the diabetes powerhouse it is today.